Evoke Pharma Stock Price Prediction

EVOK Stock  USD 4.31  0.10  2.38%   
As of now, the relative strength index (RSI) of Evoke Pharma's share price is approaching 41 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Evoke Pharma, making its price go up or down.

Oversold Vs Overbought

0

 
Oversold
 
Overbought
The successful prediction of Evoke Pharma's future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Evoke Pharma, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Evoke Pharma's stock price prediction:
EPS Estimate Next Quarter
(0.25)
EPS Estimate Current Year
(3.98)
EPS Estimate Next Year
0.48
Wall Street Target Price
18
EPS Estimate Current Quarter
(0.38)
Using Evoke Pharma hype-based prediction, you can estimate the value of Evoke Pharma from the perspective of Evoke Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Evoke Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Evoke because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Evoke Pharma after-hype prediction price

    
  USD 4.33  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Evoke Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
Intrinsic
Valuation
LowRealHigh
0.285.5711.84
Details
Naive
Forecast
LowNextHigh
0.14.7711.04
Details
1 Analysts
Consensus
LowTargetHigh
6.377.007.77
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.99-0.99-0.99
Details

Evoke Pharma After-Hype Price Prediction Density Analysis

As far as predicting the price of Evoke Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Evoke Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Evoke Pharma, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Evoke Pharma Estimiated After-Hype Price Volatility

In the context of predicting Evoke Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Evoke Pharma's historical news coverage. Evoke Pharma's after-hype downside and upside margins for the prediction period are 0.22 and 10.60, respectively. We have considered Evoke Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
4.31
4.33
After-hype Price
10.60
Upside
Evoke Pharma is unstable at this time. Analysis and calculation of next after-hype price of Evoke Pharma is based on 3 months time horizon.

Evoke Pharma Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Evoke Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evoke Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Evoke Pharma, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.35 
6.32
  0.06 
 0.00  
8 Events / Month
9 Events / Month
In about 8 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
4.31
4.33
0.46 
3,511  
Notes

Evoke Pharma Hype Timeline

Evoke Pharma is currently traded for 4.31. The entity has historical hype elasticity of 0.06, and average elasticity to hype of competition of 0.0. Evoke is estimated to increase in value after the next headline, with the price projected to jump to 4.33 or above. The average volatility of media hype impact on the company the price is over 100%. The price upswing on the next news is projected to be 0.46%, whereas the daily expected return is currently at 0.35%. The volatility of related hype on Evoke Pharma is about 46184.62%, with the expected price after the next announcement by competition of 4.31. The company reported the previous year's revenue of 5.18 M. Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 2.14 M. Given the investment horizon of 90 days the next estimated press release will be in about 8 days.
Check out Evoke Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

Evoke Pharma Related Hype Analysis

Having access to credible news sources related to Evoke Pharma's direct competition is more important than ever and may enhance your ability to predict Evoke Pharma's future price movements. Getting to know how Evoke Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Evoke Pharma may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
PTPIPetros Pharmaceuticals(0.02)4 per month 4.18  0.01  12.90 (7.89) 45.54 
CPIXCumberland Pharmaceuticals 0.08 9 per month 0.00 (0.07) 4.65 (5.19) 30.57 
AGRXAgile Thrpe 0.00 0 per month 0.00 (0.30) 7.63 (7.16) 19.82 
PRFXPainreform 0.20 4 per month 10.81  0.02  13.67 (19.48) 187.40 
AQSTAquestive Therapeutics(0.24)8 per month 4.03 (0) 6.51 (7.14) 20.93 
ADMPAdamis Pharma 0.05 4 per month 0.00 (0.28) 8.72 (11.60) 40.76 
GHSIGuardion Health Sciences 0.00 0 per month 8.11  0.05  18.66 (7.94) 101.05 
ACRXAcelRx Pharmaceuticals 0.02 1 per month 4.26  0.07  13.85 (8.26) 29.52 
EGRXEagle Pharmaceuticals 0.00 0 per month 0.00 (0.20) 9.24 (8.24) 53.71 
RGCRegencell Bioscience Holdings(0.20)10 per month 6.21 (0) 22.58 (10.93) 43.32 
PROCProcaps Group SA 0.00 0 per month 9.25  0.04  26.19 (13.75) 122.49 
IXHLIncannex Healthcare Ltd 0.02 4 per month 5.09  0.0005  10.05 (8.62) 28.99 
DERMJourney Medical Corp(0.68)6 per month 3.82  0.04  6.89 (6.06) 22.80 
JUPWJupiter Wellness 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
AVDLAvadel Pharmaceuticals PLC 0.37 9 per month 0.00 (0.14) 4.79 (5.87) 39.15 
BFRIBiofrontera 0.00 0 per month 7.49  0.01  14.63 (11.70) 46.72 
SHPHShuttle Pharmaceuticals 0.20 3 per month 0.00 (0.17) 9.22 (10.70) 50.96 
AKANAkanda Corp(0.06)2 per month 0.00 (0.11) 8.57 (7.22) 23.93 
CPHIChina Pharma Holdings 0.00 7 per month 4.63  0.02  9.09 (11.11) 43.71 

Evoke Pharma Additional Predictive Modules

Most predictive techniques to examine Evoke price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Evoke using various technical indicators. When you analyze Evoke charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Evoke Pharma Predictive Indicators

The successful prediction of Evoke Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Evoke Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Evoke Pharma based on analysis of Evoke Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Evoke Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Evoke Pharma's related companies.
 2021 2022 2023 2024 (projected)
Payables Turnover0.380.430.120.2
Days Of Inventory On Hand206.39285.16871.17648.49

Story Coverage note for Evoke Pharma

The number of cover stories for Evoke Pharma depends on current market conditions and Evoke Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Evoke Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Evoke Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Evoke Pharma Short Properties

Evoke Pharma's future price predictability will typically decrease when Evoke Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Evoke Pharma often depends not only on the future outlook of the potential Evoke Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Evoke Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding278.6 K
Cash And Short Term Investments4.7 M
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
Check out Evoke Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.37)
Revenue Per Share
7.792
Quarterly Revenue Growth
0.698
Return On Assets
(0.34)
Return On Equity
(3.50)
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.